drugset / Trial / NCT07035990
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.
Timeline
- Start
- 2025-07-23
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SION-109 | Unknown | — | Oral |
| Subject | SION-2222 | Unknown | — | Oral |
| Subject | SION-451 | Unknown | — | Oral |